Get the Stockscreener App
0.9469
6.25%
-0.0631
After Hours:
.68
-0.2669
-28.19%
Tenaya Therapeutics Inc stock is traded at $0.9469, with a volume of 1.31M.
It is down -6.25% in the last 24 hours and down -9.82% over the past month.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
See More
Previous Close:
$1.01
Open:
$1.02
24h Volume:
1.31M
Relative Volume:
0.35
Market Cap:
$75.01M
Revenue:
-
Net Income/Loss:
$-117.23M
P/E Ratio:
-0.6576
EPS:
-1.44
Net Cash Flow:
$-95.25M
1W Performance:
-12.32%
1M Performance:
-9.82%
6M Performance:
-62.57%
1Y Performance:
-85.80%
1-Day Range:
$0.94
$1.025
1-Week Range:
$0.94
$1.09
52-Week Range:
$0.8606
$7.01
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
Name
Tenaya Therapeutics Inc
Sector
Industry
Phone
415-865-2066
Address
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
Compare TNYA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.9469 | 75.01M | 0 | -117.23M | -95.25M | -1.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-24 | Initiated | William Blair | Outperform |
| Nov-30-23 | Initiated | Leerink Partners | Outperform |
| Jun-15-22 | Initiated | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc Stock (TNYA) Latest News
Tenaya Therapeutics announces securities offering - Investing.com India
Tenaya Therapeutics Announces Proposed Offering of Common Stock and Warrants - Nasdaq
Tenaya Therapeutics Announces Proposed Public Offering - GlobeNewswire
Heart Disease Biotech Tenaya Seeks Fresh Capital Through Complex Warrant Offering - StockTitan
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences - The Manila Times
Can Tenaya's Heart Disease Therapies Impress Investors at March Conferences? - StockTitan
H.C. Wainwright maintains buy rating on Tenaya Therapeutics stock - MSN
Monitoring Tenaya Therapeutics Inc (TNYA) after recent insider movements - Knox Daily
Head to Head Survey: Tenaya Therapeutics (NASDAQ:TNYA) and PharmaCyte Biotech (OTCMKTS:PMCBD) - Defense World
Taking on analysts’ expectations and winning: Tenaya Therapeutics Inc (TNYA) - SETE News
SG Americas Securities LLC Purchases 15,777 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA) - Defense World
It is Poised to be a Bull Market for Tenaya Therapeutics Inc (TNYA) - SETE News
Technical analysis of Tenaya Therapeutics Inc (TNYA) stock chart patterns - US Post News
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Tenaya Therapeutics appoints new interim principal accounting officer - MSN
Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Target Price at $17.33 - Defense World
Tenaya Therapeutics appoints new interim principal accounting officer By Investing.com - Investing.com Canada
Tenaya Therapeutics Appoints Interim Accounting Officer - TipRanks
Tenaya Therapeutics Inc (TNYA) Stock: A Year of Market Fluctuations - The InvestChronicle
BlackRock, Inc. Acquires Additional Shares in Tenaya Therapeutics Inc - GuruFocus.com
A History of Outperforming Analyst Forecasts and Beating the Odds: Tenaya Therapeutics Inc (TNYA) - SETE News
Tenaya Therapeutics (NASDAQ:TNYA) Earns "Buy" Rating from HC Wainwright - MarketBeat
Recent Insider Activity Suggests Potential Gains for Tenaya Therapeutics Inc (TNYA) - Knox Daily
Tenaya Therapeutics (NASDAQ:TNYA) Earns “Buy” Rating from HC Wainwright - Defense World
Analyze Tenaya Therapeutics Inc (NASDAQ: TNYA) Before Investing. - Stocks Register
Market Watch Highlights: Tenaya Therapeutics Inc (TNYA) Ends on an Downturn Note at 1.05 - The Dwinnex
Is Tenaya Therapeutics Inc (TNYA) a good investment opportunity? - US Post News
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine - GlobeNewswire
TNYATenaya Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Tenaya Therapeutics receives $8M clinical grant from CIRM - MSN
Promising Potential of Tenaya Therapeutics: Buy Rating Justified by Financial Backing and Clinical Progress - TipRanks
Major Funding Breakthrough: Rare Heart Disease Gene Therapy Trial Gets $8M Boost - StockTitan
Tenaya Therapeutics announces option repricing to retain staff - MSN
Tenaya Therapeutics announces option repricing to retain staff By Investing.com - Investing.com Australia
Tenaya Therapeutics Reprices Underwater Stock Options - TipRanks
Here's Why Tenaya Therapeutics (NASDAQ:TNYA) Must Use Its Cash Wisely - Simply Wall St
Tenaya Therapeutics (TNYA) Stock Price, News & Analysis - MarketBeat
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by Jane Street Group LLC - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives $17.33 Average PT from Brokerages - MarketBeat
Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) PT at $17.33 - Defense World
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Short Interest Update - MarketBeat
HC Wainwright Reiterates Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA) - MarketBeat
Tenaya advances gene therapies for heart conditions By Investing.com - Investing.com Canada
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - GlobeNewswire
Tenaya Therapeutics Inc Stock (TNYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.13%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):